SEC Form 4 · accession 0001213900-18-009317
Actinium Pharmaceuticals, Inc. · ATNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sandesh Seth
Officer — CEO · Director
Period of report
Jul 13, 2018
Accepted (ET)
Jul 17, 2018 · 5:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001388320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock | Jul 17, 2018 | P | 10,000 | $0.79 | A | 143,333 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchase common stockF1 | $0.7829 | Jul 13, 2018 | A | 1,000,000 | A | Jul 13, 2018 | Jul 13, 2028 | Common Stock | 1,000,000 | 1,000,000 | D |
Explanation of responses
- F1Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant.